




RealRate

PHARMACEUTICAL 2024

Enanta Pharmaceuticals INC
Rank 146 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Enanta Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enanta Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Enanta Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 14% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	422,791
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	62,787
Liabilities, Non-Current	21,901
Other Assets	27,565
Other Compr. Net Income	2,550
Other Expenses	2,821
Other Liabilities	160,852
Other Net Income	6,212
Other Revenues	79,204
Property and Equipment	11,919
Research and Development	163,524
Selling, General and Administrative Expense	52,887

Output Variable	Value in 1000 USD
Assets	462,275
Liabilities	245,540
Expenses	219,232
Revenues	79,204
Stockholders Equity	216,735
Net Income	-133,816
Comprehensive Net Income	-132,541
BaseVar	507,506
ECR before LimitedLiability	96%
Economic Capital Ratio	227%